Vaxart Inc. has announced the receipt of substantial funding for its ongoing COVID-19 vaccine development efforts. The funding, valued at up to $460.7 million, comes under Project NextGen, an initiative by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services $(HHS)$. This initiative, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), aims to accelerate the development of next-generation COVID-19 vaccines and therapeutics. Vaxart's project is supported through the Rapid Response Partnership Vehicle (RRPV) Consortium, highlighting a collaborative effort with multiple organizations to advance innovative vaccine solutions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.